Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 169
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C89EC034F74EN
Leaflet:

Download PDF Leaflet

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 8, 7, 3, 18, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 8, 5 and 5 molecules, respectively.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Cytomegalovirus (HHV-5) Infections - Overview
Cytomegalovirus (HHV-5) Infections - Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Drug Profiles
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Therapeutics Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Thea Laboratories SA, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Vectorite Biomedica Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H2 2017
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2017
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2017 (Contd..3), H2 2017
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AIMM Therapeutics BV
Astellas Pharma Inc
Atara Biotherapeutics Inc
AvidBiotics Corp
Biotest AG
Chimerix Inc
China Biologic Products Inc
CyTuVax BV
Fate Therapeutics Inc
GlaxoSmithKline Plc
Hookipa Biotech AG
Kadmon Corp LLC
Merck & Co Inc
Moderna Therapeutics Inc
Novartis AG
Pfizer Inc
Phoenix Biotechnology Inc
Qurient Co Ltd
Sigma-Tau SpA
Thea Laboratories SA
Themis Bioscience GmbH
Trellis Bioscience Inc
Vakzine Projekt Management GmbH
VBI Vaccines Inc
Vectorite Biomedica Inc
Vical Inc
Skip to top


Ask Your Question

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: